Intelligence · Drug directory
Withdrawn Drug Applications
Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.
Quick answer
Withdrawn applications: NovaPharmaNews tracks 229 pharmaceutical drugs in this segment. Drugs with withdrawn or discontinued regulatory applications in the US or EU — useful for competitive and label-history research.
-
fosamprenavir
TELZIR
J05AE07 -
garenoxacin mesylate
GARENOXACIN MESYLATE
-
gbp510
SKYCOVION
J07BX03 -
govorestat
NUGALVIQ
A16AX24 -
gusperimus
SPANIDIN
-
hepatitis b surface antigens recombinant (s, pre-s1, pre-s2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (c127i) cells]
HEPACARE
J07BC -
human coagulation factor ix
NONAFACT
B02BD04 -
ibalizumab
TROGARZO
J05AX -
igovomab
INDIMACIS 125
V09IB03 -
indinavir
CRIXIVAN
J05AE02 -
infigratinib
FEBSELTIQ
L01E -
influenza vaccine (h1n1)v (whole virion, vero cell derived, inactivated)
CELVAPAN
J07BB01 -
influenza vaccine (split virion, inactivated)
INTANZA
J07BB02 -
interferon alfa-2b
INTRONA
L03AB05 -
interferon alfacon-1
INFERGEN
L03AB09 -
iron oxide
SINEREM
-
laropiprant
TREVACLYN
C10AD52 -
lenadogene nolparvovec
LUMEVOQ
S01 -
lepirudin
REFLUDAN
B01AE02 -
levacetylmethadol
ORLAAM
N02AC -
lisuride
NENAD
-
mangafodipir
TESLASCAN
V08CA05 -
maralixibat
LIVMARLI
A05AX -
mecasermin rinfabate
IPLEX
Frequently asked questions
How many withdrawn drugs are listed?
229 drug profiles match this regulatory segment in our published index.
Where does approval data come from?
Profiles combine FDA Drugs@FDA, EMA EPAR references, and regional authority feeds. See our data sources page for attribution.